Trials / Completed
CompletedNCT03895684
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Salarius Pharmaceuticals, LLC · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.
Detailed description
Phase 1, open-label, non-randomized dose finding study of SP-2577 given as oral tablets in patients with advanced solid tumors in 28-day cycles. The study design is based on a Simon's 4B design without intrapatient dose escalation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SP-2577 Seclidemstat | Dose escalation and dose expansion of SP-2577. |
Timeline
- Start date
- 2019-06-25
- Primary completion
- 2021-04-13
- Completion
- 2021-04-13
- First posted
- 2019-03-29
- Last updated
- 2021-10-18
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03895684. Inclusion in this directory is not an endorsement.